| 抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响 |
| |
| 引用本文： | 抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响.抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响[J].首都医学院学报,2018,39(6):810-814. |
| |
| 作者姓名： | 抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响 |
| |
| 作者单位： | 1. 首都医科大学密云教学医院中医科, 北京 101500;2. 首都医科大学附属北京地坛医院中西医结合中心, 北京 100015 |
| |
| 基金项目： | 国家自然科学基金（81503607），北京市医院管理局临床医学发展专项（ZYLX201510），北京市医院管理局"登峰"计划专项（DFL20151301）。 |
| |
| 摘 要： | 目的 探讨抗病毒基础上联合中医药治疗对乙型肝炎e抗原（hepatitis B e antigen，HBeAg）阳性的慢性乙型肝炎患者HBeAg血清转换率的影响。方法 将符合纳入标准的679名HBeAg阳性慢性乙型肝炎的患者，根据是否联合应用中医药治疗分为抗病毒西药组（209例）和中西药联合组（470例），观察治疗1年后 HBeAg血清学转换率，分层分析联合治疗的优势人群。结果 治疗1年后，抗病毒西药组和中西药联合组HBeAg血清学转换率分别为11.5%和12.8%（P=0.66）；应用课题组前期建立的评分模型分层分析显示，评分0~1分的患者，抗病毒西药组和中西药联合组HBeAg血清学转换率分别为2.6%和8.1%（P=0.04）。结论 抗病毒基础上联合中医药治疗能够提高评分为0~1分的慢性乙型肝炎患者HBeAg血清学转换率。
|
| 关 键 词： | 慢性乙型肝炎 慢性乙型肝炎e抗原血清学转换 抗病毒治疗 评分模型 中医药治疗 联合治疗 |
| 收稿时间： | 2018-09-20 |
Antivirals therapy combined with traditional Chinese medicine effects on HBeAg seroconversion rate in patients with chronic hepatitis B |
| |
| Geng Mingfan,Gao Fangyuan,Li Yuxin,Zhang Qun,Liu Yao,Wang Xianbo.Antivirals therapy combined with traditional Chinese medicine effects on HBeAg seroconversion rate in patients with chronic hepatitis B[J].Journal of Capital University of Medical Sciences,2018,39(6):810-814. |
| |
| Authors: | Geng Mingfan Gao Fangyuan Li Yuxin Zhang Qun Liu Yao Wang Xianbo |
| |
| Affiliation: | 1. Department of Traditional Chinese Medicine, Miyun Education Hospital, Capital Medical University, Beijing 101500, China;2. The Center of Integrated Traditional and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China |
| |
| Abstract: | Objective To investigate the effect of antivirals therapy combined with traditional Chinese medicine therapy on hepatitis B e antigen (HBeAg) seroconversion rate in patients with HBeAg-positive chronic hepatitis B. Methods The 679 HBeAg-positive chronic hepatitis B patients who met the inclusion criteria were divided into the antiviral western medicine group (209 patients) and the Chinese and western medicine combination group (470 patients) according to whether or not they were treated with traditional Chinese medicine. The HBeAg seroconversion rate was observed after 1 year of treatment, and stratified sampling was applied to identify the dominant population of combined therapy. Results After 1 year of the treatment, the seroconversion rate of HBeAg in the antiviral western medicine group and the combined group was 11.5% and 12.8%, respectively, with P=0.66. The patients were scored with the scoring model that our group established in the early stage. For those patients with a score of 0-1 in the antiviral western medicine group and combined therapy group,HBeAg conversion rates were 2.6% and 8.1%, respectively, with P=0.04. Conclusion On the basis of antiviral treatment, combined Chinese medicine treatment can improve the HBeAg seroconversion rate of chronic hepatitis B patients with a score of 0-1. |
| |
| Keywords: | chronic hepatitis B hepatitis B e antigen seroconversion antiviral therapy scoring model Chinese medicine treatment combination therapy |
|
| 点击此处可从《首都医学院学报》浏览原始摘要信息 |
|
点击此处可从《首都医学院学报》下载全文 |
